Welcome to LookChem.com Sign In|Join Free
  • or
6,7-Dimethoxy-4-[N-(3-chlorophenyl)amino]quinazoline hydrochloride is a member of the quinazoline class, characterized by the presence of methoxy groups at positions 6 and 7, and a (3-chlorophenyl)nitrilo group at position 4. 6,7-Dimethoxy-4-[N-(3-chlorophenyl)amino]quinazoline hydrochloride functions as an antagonist of the epidermal growth factor receptor, making it a potential candidate for pharmaceutical applications.

170449-18-0

Post Buying Request

170449-18-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

170449-18-0 Usage

Uses

Used in Pharmaceutical Industry:
6,7-Dimethoxy-4-[N-(3-chlorophenyl)amino]quinazoline hydrochloride is used as an epidermal growth factor receptor antagonist for targeting various types of cancer. Its ability to inhibit the epidermal growth factor receptor can lead to the suppression of tumor growth and progression, making it a promising agent in cancer treatment.
Used in Drug Development:
In the field of drug development, 6,7-Dimethoxy-4-[N-(3-chlorophenyl)amino]quinazoline hydrochloride serves as a key compound for the design and synthesis of novel therapeutic agents. Its antagonistic properties against the epidermal growth factor receptor can be leveraged to create new drugs with improved efficacy and selectivity for treating cancer and other related diseases.
Used in Research and Development:
6,7-Dimethoxy-4-[N-(3-chlorophenyl)amino]quinazoline hydrochloride is also utilized in research and development for studying the mechanisms of action and potential side effects of epidermal growth factor receptor antagonists. This knowledge can contribute to the optimization of drug candidates and the development of safer and more effective treatments for various medical conditions.

Check Digit Verification of cas no

The CAS Registry Mumber 170449-18-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,0,4,4 and 9 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 170449-18:
(8*1)+(7*7)+(6*0)+(5*4)+(4*4)+(3*9)+(2*1)+(1*8)=130
130 % 10 = 0
So 170449-18-0 is a valid CAS Registry Number.
InChI:InChI=1/C16H14ClN3O2.ClH/c1-21-14-7-12-13(8-15(14)22-2)18-9-19-16(12)20-11-5-3-4-10(17)6-11;/h3-9H,1-2H3,(H,18,19,20);1H

170449-18-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name N-(3-Chlorophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride

1.2 Other means of identification

Product number -
Other names N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine,hydrochloride

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:170449-18-0 SDS

170449-18-0Downstream Products

170449-18-0Relevant academic research and scientific papers

Design, synthesis, and DNA-binding of N-alkyl(anilino)quinazoline derivatives

Garofalo, Antonio,Goossens, Laurence,Baldeyrou, Brigitte,Lemoine, Amélie,Ravez, Séverine,Six, Perrine,David-Cordonnier, Marie-Hélène,Bonte, Jean-Paul,Depreux, Patrick,Lansiaux, Amélie,Goossens, Jean-Fran?ois

experimental part, p. 8089 - 8103 (2011/03/17)

New N-alkylanilinoquinazoline derivatives 5, 12, 20, and 22 have been prepared from 4-chloro-6,7-dimethoxyquinazoline 3, 4-chloro-6,7- methylenedioxyquinazoline 19, and commercially available anilines. Differents classes of compounds substituted by an aryloxygroup (6a-c, 16a,b, and 17a,b), (aminophenyl)ureas (12a,b and 13a-f), anilines (4a-m, 20a,b), N-alkyl(aniline) (5a-m, 21a,b, 22a,d), and N-aminoalkyl(aniline) (22e-g) have been synthesized. These molecules were evaluated for their cytotoxic activities and as potential DNA intercalating agents. We studied the strength and mode of binding to DNA of these molecules by DNA melting temperature measurements, fluorescence emission, and circular dichroism. The results of various spectral and gel electrophoresis techniques obtained with the different compounds, in particular compounds 5g and 22f, revealed significant DNA interaction. These experiments confirm that the N-aminoalkyl(anilino)-6,7-dimethoxyquinazoline nucleus is an efficient pharmacophore to trigger binding to DNA, via an intercalative binding process.

Anilinodialkoxyquinazolines: Screening epidermal growth factor receptor tyrosine kinase inhibitors for potential tumor imaging probes

VanBrocklin, Henry F.,Lim, John K.,Coffing, Stephanie L.,Hom, Darren L.,Negash, Kitaw,Ono, Michele Y.,Gilmore, Jennifer L.,Bryant, Ianthe,Riese II, David J.

, p. 7445 - 7456 (2007/10/03)

The epidermal growth factor receptor (EGFR), a long-standing drug development target, is also a desirable target for imaging. Sixteen dialkoxyquinazoline analogues, suitable for labeling with positron-emitting isotopes, have been synthesized and evaluated in a battery of in vitro assays to ascertain their chemical and biological properties. These characteristics provided the basis for the adoption of a selection schema to identify lead molecules for labeling and in vivo evaluation. A new EGFR tyrosine kinase radiometric binding assay revealed that all of the compounds possessed suitable affinity (IC50 = 0.4-51 nM) for the EGFR tyrosine kinase. All of the analogues inhibited ligand-induced EGFR tyrosine phosphorylation (IC 50 = 0.8-20 nM). The HPLC-estimated octanol/water partition coefficients ranged from 2 to 5.5. Four compounds, 4-(2′-fluoroanilino)- and 4-(3′-fluoroanilino)-6,7-diethoxyquinazoline as well as 4-(3′-chloroanilino)- and 4-(3′-bromoanilino)-6,7- dimethoxyquinazoline, possess the best combination of characteristics that warrant radioisotope labeling and further evaluation in tumor-bearing mice.

COMPOUNDS DERIVED FROM 4--ANILINEQUINAZOLINES WITH ADENOSINE-KIASE INHIBITOR PROPERTIES

-

Page/Page column 22-23, (2008/06/13)

The present invention introduces compounds that are adenosine-kinase inhibitors. We provide a process of protecting tissues and organs like heart, brain and kidneys affected by ischemia, and of treating heart insufficiency, myocardium infarct, arrhythmia, arterial hypertension, atherosclerosis, coronary artery re-stenosis after angioplasty, chronic renal insufficiency, cerebral vascular accident, and chronic inflammatory diseases (e.g. rheumatoid arthritis). We also provide the adenosine-kinase inhibitor effect of compounds derived from quinazolines, which were previously known as reversible inhibitors of tyrosine-kinases from the family of epidermic growth factor receptors (EGFR).

Syntheses of Some 4-Anilinoquinazoline Derivatives

Rocco, Silvana A.,Barbarini, Jose Eduardo,Rittner, Roberto

, p. 429 - 435 (2007/10/03)

Some 4-N-(3′- or 4′-substituted-phenyl)amino-6,7- dimethoxyquinazolines and the corresponding unsubstituted compounds were synthesized from 2-amino-4,5-dimethoxybenzoic acid and the appropriate substituted anilines. Other related quinazolines or their synthetic intermediates were also obtained. A large number of the described quinazolines are new compounds, while the remaining were prepared by a more efficient procedure. The main goal for the synthesis of these compounds comes from the fact that the 4-anilinoquinazoline pharmacophore is an important unit, which is found among the ATP-competitive inhibitors of several protein kinase enzymes.

The preparation and SAR of 4-(anilino), 4-(phenoxy), and 4-(thiophenoxy)-quinazolines: Inhibitors of p56(lck) and EGF-R tyorsine kinase activity

Myers, Michael R.,Setzer, Natalie N.,Spada, Alfred P.,Zulli, Allison L.,Hsu, Chin-Yi J.,Zilberstein, Asher,Johnson, Susan E.,Hook, Linda E.,Jacoski, Mary V.

, p. 417 - 420 (2007/10/03)

We report herein our preliminary results of a SAR study of quinazoline-based inhibitors of p56(lck) and EGF-R tyrosine kinase activity. The most potent inhibitor of p56(lck) identified, RPR-108518A (10), has an IC50 of 0.50 μM. The 3-chlorophenoxy- and 3-chlorothiophenoxy- derivatives 5 and 6 were also shown to be extremely potent EGF-R inhibitors.

Tyrphostins IV - Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines

Gazit, Aviv,Chen, Jeffrey,Harald, App,McMahon, Gerald,Hirth, Peter,Chen, Irit,Levitzki, Alexander

, p. 1203 - 1207 (2007/10/03)

Potent 4-anilido-substituted quinazolines which potently inhibit epidermal growth factor receptor (EGFR) kinase were prepared. Structure-activity relationship studies reveal high sensitivity to substitution at the aniline ring.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 170449-18-0